On this episode of Biztech’s Health & Wellness show, we featured Raman Singh the CEO of Juniper Biologics.
Juniper Biologics is is a science-led healthcare company headquartered in Singapore with a global presence in China, Japan, Asia, Australia, New Zealand, the Middle East, and Africa. The company focuses on researching, developing, and commercializing novel therapies.
Raman share’s insights on Juniper Biologics ventures into novel therapies and bio-innovations as well as the ever changing bio landscape
Key Takeaways :
- Gene Therapy for Knee Pain: Juniper Biologics is working on a groundbreaking gene therapy to address knee pain and potentially eliminate the need for knee replacements. This therapy aims to fill an unmet need, especially in regions with aging populations.
- Rare Diseases: The company is also dedicated to addressing rare diseases, recognizing that while these conditions affect a small portion of the population, they represent a significant burden for those individuals. Their focus includes innovative medications for these conditions.
- Market Focus: Juniper Biologics has strategically positioned itself to serve the Asia-Pacific, Australia, New Zealand, and the Middle East and Africa, areas often overlooked by other pharmaceutical companies. They concentrate on innovative medications and therapies rather than generics.
- Investment and Funding: The company secured investments from private equity and venture capital firms, enabling them to expand their operations and acquire assets for inorganic growth. They are currently financially stable and profitable.
- Changing Landscape in Biotech: The biotech industry is evolving rapidly, with the potential for innovative companies to make a significant impact in healthcare. It’s essential to focus on products that make a difference, collaborate with the right partners, and build a cohesive, visionary team.
Guest : Raman Singh the CEO of Juniper Biologics
Host : Brian Fernandez
For more on such conversations click here